Insider Selling: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Insider Sells 1,326 Shares of Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) insider James Kihara sold 1,326 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $16.94, for a total transaction of $22,462.44. Following the completion of the sale, the insider now owns 14,370 shares of the company’s stock, valued at $243,427.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

James Kihara also recently made the following trade(s):

• On Monday, April 8th, James Kihara sold 1,790 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $17.87, for a total value of $31,987.30.
• On Monday, February 26th, James Kihara sold 474 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $24.67, for a total value of $11,693.58.

ACADIA Pharmaceuticals Stock Performance

Shares of NASDAQ ACAD opened at $17.05 on Friday. The company has a market capitalization of $2.82 billion, a PE ratio of -44.87 and a beta of 0.42. The company’s fifty day moving average price is $19.15 and its 200 day moving average price is $23.33. ACADIA Pharmaceuticals Inc. has a 1 year low of $16.16 and a 1 year high of $33.99.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.04). ACADIA Pharmaceuticals had a negative return on equity of 15.67% and a negative net margin of 8.44%. The firm had revenue of $231.04 million during the quarter, compared to analyst estimates of $223.79 million. During the same quarter last year, the company posted ($0.26) EPS. The company’s revenue was up 69.3% on a year-over-year basis. On average, equities analysts expect that ACADIA Pharmaceuticals Inc. will post 0.62 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Tuesday, April 9th. Morgan Stanley reduced their target price on ACADIA Pharmaceuticals from $40.00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday, March 13th. HC Wainwright reaffirmed a “buy” rating and set a $33.00 price target on shares of ACADIA Pharmaceuticals in a research report on Wednesday, February 28th. Cantor Fitzgerald reissued an “overweight” rating and issued a $37.00 price objective on shares of ACADIA Pharmaceuticals in a report on Tuesday, April 30th. Finally, Robert W. Baird assumed coverage on ACADIA Pharmaceuticals in a report on Tuesday, January 30th. They set an “outperform” rating and a $40.00 target price for the company. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $32.13.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. RTW Investments LP raised its stake in shares of ACADIA Pharmaceuticals by 18.3% during the 3rd quarter. RTW Investments LP now owns 11,576,537 shares of the biopharmaceutical company’s stock worth $241,255,000 after buying an additional 1,793,288 shares during the period. Norges Bank acquired a new position in ACADIA Pharmaceuticals during the fourth quarter worth $45,187,000. Fred Alger Management LLC raised its position in ACADIA Pharmaceuticals by 38.7% during the third quarter. Fred Alger Management LLC now owns 3,108,883 shares of the biopharmaceutical company’s stock worth $64,789,000 after acquiring an additional 867,818 shares during the period. Eventide Asset Management LLC purchased a new position in ACADIA Pharmaceuticals during the fourth quarter valued at $25,342,000. Finally, M&G Investment Management Ltd. acquired a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter valued at about $10,349,000. Hedge funds and other institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.